Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 189

1.

Hepatocellular carcinoma.

Forner A, Reig M, Bruix J.

Lancet. 2018 Jan 4. pii: S0140-6736(18)30010-2. doi: 10.1016/S0140-6736(18)30010-2. [Epub ahead of print] Review.

PMID:
29307467
2.

A systematic review and network meta-analysis of post-imatinib therapy in advanced gastrointestinal stromal tumour.

Shah K, Chan KKW, Ko YJ.

Curr Oncol. 2017 Dec;24(6):e531-e539. doi: 10.3747/co.24.3463. Epub 2017 Dec 20. Review.

3.

Systemic Therapy for Hepatocellular Carcinoma: 2017 Update.

Kudo M.

Oncology. 2017;93 Suppl 1:135-146. doi: 10.1159/000481244. Epub 2017 Dec 20. Review.

4.

Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions.

Ray EM, Sanoff HK.

J Hepatocell Carcinoma. 2017 Nov 8;4:131-138. doi: 10.2147/JHC.S124366. eCollection 2017. Review.

5.

Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review.

Røed Skårderud M, Polk A, Kjeldgaard Vistisen K, Larsen FO, Nielsen DL.

Cancer Treat Rev. 2018 Jan;62:61-73. doi: 10.1016/j.ctrv.2017.10.011. Epub 2017 Nov 10. Review.

PMID:
29175677
6.

Regorafenib -- Addendum to Commission A15-43 [Internet].

Institute for Quality and Efficiency in Health Care.

Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2016 Feb 26.

7.

Regorafenib -- Benefit Assessment According to §35a Social Code Book V [Internet].

Institute for Quality and Efficiency in Health Care.

Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2015 Dec 23.

8.

Enzymes involved in tumor-driven angiogenesis: A valuable target for anticancer therapy.

Ricciuti B, Foglietta J, Bianconi V, Sahebkar A, Pirro M.

Semin Cancer Biol. 2017 Nov 8. pii: S1044-579X(17)30043-3. doi: 10.1016/j.semcancer.2017.11.005. [Epub ahead of print] Review.

PMID:
29128510
9.

Hepatocellular carcinoma: Present and future.

Armengol C, Sarrias MR, Sala M.

Med Clin (Barc). 2017 Oct 30. pii: S0025-7753(17)30717-0. doi: 10.1016/j.medcli.2017.08.010. [Epub ahead of print] Review. English, Spanish.

PMID:
29096967
10.
11.

Emerging combination therapies for metastatic colorectal cancer - impact of trifluridine/tipiracil.

Puthiamadathil JM, Weinberg BA.

Cancer Manag Res. 2017 Oct 3;9:461-469. doi: 10.2147/CMAR.S113320. eCollection 2017. Review.

12.

A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer.

Ciombor KK, Bekaii-Saab T.

Oncologist. 2018 Jan;23(1):25-34. doi: 10.1634/theoncologist.2017-0203. Epub 2017 Oct 11. Review.

PMID:
29021377
13.

Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy.

Sunakawa Y, Izawa N, Mizukami T, Horie Y, Hirakawa M, Arai H, Ogura T, Tsuda T, Nakajima TE.

Onco Targets Ther. 2017 Sep 15;10:4599-4605. doi: 10.2147/OTT.S106101. eCollection 2017. Review.

14.

Treatment-related serious adverse events and fatal adverse events with regorafenib in cancer patients: a meta-analysis of phase 3 randomized controlled trials.

Cao M, Li F, Wang Y, Zhang J.

Invest New Drugs. 2017 Dec;35(6):834-838. doi: 10.1007/s10637-017-0512-6. Epub 2017 Sep 22. Review.

PMID:
28936569
15.

Chemotherapy for Hepatocellular Carcinoma: Current Evidence and Future Perspectives.

Rinninella E, Cerrito L, Spinelli I, Cintoni M, Mele MC, Pompili M, Gasbarrini A.

J Clin Transl Hepatol. 2017 Sep 28;5(3):235-248. doi: 10.14218/JCTH.2017.00002. Epub 2017 Jun 8. Review.

16.

Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis.

Chebib R, Verlingue L, Cozic N, Faron M, Burtin P, Boige V, Hollebecque A, Malka D.

Semin Oncol. 2017 Apr;44(2):114-128. doi: 10.1053/j.seminoncol.2017.07.004. Epub 2017 Aug 2. Review.

PMID:
28923209
17.

An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma.

Raoul JL, Gilabert M, Adhoute X, Edeline J.

Expert Opin Pharmacother. 2017 Oct;18(14):1467-1476. doi: 10.1080/14656566.2017.1378346. Epub 2017 Sep 14. Review.

PMID:
28893090
18.

Inclusion of elderly or frail patients in randomized controlled trials of targeted therapies for the treatment of metastatic colorectal cancer: A systematic review.

Gouverneur A, Salvo F, Berdaï D, Moore N, Fourrier-Réglat A, Noize P.

J Geriatr Oncol. 2018 Jan;9(1):15-23. doi: 10.1016/j.jgo.2017.08.001. Epub 2017 Aug 24. Review.

PMID:
28844343
19.

Chemotherapy for hepatocellular carcinoma: The present and the future.

Le Grazie M, Biagini MR, Tarocchi M, Polvani S, Galli A.

World J Hepatol. 2017 Jul 28;9(21):907-920. doi: 10.4254/wjh.v9.i21.907. Review.

20.

Recent developments in the treatment of metastatic colorectal cancer.

Loree JM, Kopetz S.

Ther Adv Med Oncol. 2017 Aug;9(8):551-564. doi: 10.1177/1758834017714997. Epub 2017 Jun 29. Review.

Supplemental Content

Loading ...
Support Center